Back to Search
Start Over
Merck: V116 vaccine for pneumococcal diseases show adult immune response
- Source :
- The Fly. March 19, 2024
- Publication Year :
- 2024
-
Abstract
- Merck announced positive data from multiple Phase 3 studies evaluating V116, the company's investigational, adult-specific 21-valent pneumococcal conjugate vaccine, at the 13th Meeting of the International Society of Pneumonia and [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- The Fly
- Publication Type :
- Periodical
- Accession number :
- edsgcl.786844593